Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 7 de 7
1.
PLoS One ; 19(4): e0300098, 2024.
Article En | MEDLINE | ID: mdl-38625996

The structural morphology of coronary stents and the local hemodynamic environment following stent deployment in coronary arteries are crucial determinants of procedural success and subsequent clinical outcomes. High-resolution intracoronary imaging has the potential to facilitate geometrically accurate three-dimensional (3D) reconstruction of coronary stents. This work presents an innovative algorithm for the 3D reconstruction of coronary artery stents, leveraging intravascular ultrasound (IVUS) and angiography. The accuracy and reproducibility of our method were tested in stented patient-specific silicone models, with micro-computed tomography serving as a reference standard. We also evaluated the clinical feasibility and ability to perform computational fluid dynamics (CFD) studies in a clinically stented coronary bifurcation. Our experimental and clinical studies demonstrated that our proposed algorithm could reproduce the complex 3D stent configuration with a high degree of precision and reproducibility. Moreover, the algorithm was proved clinically feasible in cases with stents deployed in a diseased coronary artery bifurcation, enabling CFD studies to assess the hemodynamic environment. In combination with patient-specific CFD studies, our method can be applied to stenting optimization, training in stenting techniques, and advancements in stent research and development.


Coronary Artery Disease , Coronary Vessels , Humans , Coronary Vessels/diagnostic imaging , Coronary Vessels/surgery , Coronary Vessels/anatomy & histology , X-Ray Microtomography , Imaging, Three-Dimensional , Feasibility Studies , Reproducibility of Results , Stents , Ultrasonography, Interventional , Coronary Angiography/methods , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/surgery
3.
J Med Imaging (Bellingham) ; 11(1): 014004, 2024 Jan.
Article En | MEDLINE | ID: mdl-38173655

Purpose: Optical coherence tomography has emerged as an important intracoronary imaging technique for coronary artery disease diagnosis as it produces high-resolution cross-sectional images of luminal and plaque morphology. Precise and fast lumen segmentation is essential for efficient OCT morphometric analysis. However, due to the presence of various image artifacts, including side branches, luminal blood artifacts, and complicated lesions, this remains a challenging task. Approach: Our research study proposes a rapid automatic segmentation method that utilizes nonuniform rational B-spline to connect limited pixel points and identify the edges of the OCT lumen. The proposed method suppresses image noise and accurately extracts the lumen border with a high correlation to ground truth images based on the area, minimal diameter, and maximal diameter. Results: We evaluated the method using 3300 OCT frames from 10 patients and found that it achieved favorable results. The average time taken for automatic segmentation by the proposed method is 0.17 s per frame. Additionally, the proposed method includes seamless vessel reconstruction following the lumen segmentation. Conclusions: The developed automated system provides an accurate, efficient, robust, and user-friendly platform for coronary lumen segmentation and reconstruction, which can pave the way for improved assessment of the coronary artery lumen morphology.

4.
Sci Rep ; 13(1): 13031, 2023 08 10.
Article En | MEDLINE | ID: mdl-37563354

Coronary bifurcation lesions represent a challenging anatomical subset, and the understanding of their 3D anatomy and plaque composition appears to play a key role in devising the optimal stenting strategy. This study proposes a new approach for the 3D reconstruction of coronary bifurcations and plaque materials by combining intravascular ultrasound (IVUS) and angiography. Three patient-specific silicone bifurcation models were 3D reconstructed and compared to micro-computed tomography (µCT) as the gold standard to test the accuracy and reproducibility of the proposed methodology. The clinical feasibility of the method was investigated in three diseased patient-specific bifurcations of varying anatomical complexity. The IVUS-based 3D reconstructed bifurcation models showed high agreement with the µCT reference models, with r2 values ranging from 0.88 to 0.99. The methodology successfully 3D reconstructed all the patient bifurcations, including plaque materials, in less than 60 min. Our proposed method is a simple, time-efficient, and user-friendly tool for accurate 3D reconstruction of coronary artery bifurcations. It can provide valuable information about bifurcation anatomy and plaque burden in the clinical setting, assisting in bifurcation stent planning and education.


Coronary Artery Disease , Plaque, Atherosclerotic , Humans , Coronary Angiography/methods , Coronary Vessels/diagnostic imaging , Coronary Vessels/surgery , Imaging, Three-Dimensional/methods , Reproducibility of Results , X-Ray Microtomography , Ultrasonography, Interventional , Plaque, Atherosclerotic/diagnostic imaging , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/surgery
5.
AIMS Public Health ; 9(2): 262-277, 2022.
Article En | MEDLINE | ID: mdl-35634019

Since the inception of the current pandemic, COVID-19 related misinformation has played a role in defaulting control of the situation. It has become evident that the internet, social media, and other communication outlets with readily available data have contributed to the dissemination and availability of misleading information. It has perpetuated beliefs that led to vaccine avoidance, mask refusal, and utilization of medications with insignificant scientific data, ultimately contributing to increased morbidity. Undoubtedly, misinformation has become a challenge and a burden to individual health, public health, and governments globally. Our review article aims at providing an overview and summary regarding the role of media, other information outlets, and their impact on the pandemic. The goal of this article is to increase awareness of the negative impact of misinformation on the pandemic. In addition, we discuss a few recommendations that could aid in decreasing this burden, as preventing the conception and dissemination of misinformation is essential.

6.
Pan Afr Med J ; 43: 198, 2022.
Article En | MEDLINE | ID: mdl-36942140

Baclofen was approved for medical use in the United States in 1977 by Food and Drug Administration. Serious adverse effects associated with this medication are uncommon at usually prescribed doses. Herein, we present a case of baclofen-induced catatonia in a young-adult female with back pain receiving oral baclofen. A 20-year-old female presented to the emergency department with possible seizure-like activity. It was reported that the patient was suffering from acute back pain and was prescribed baclofen three times a day by her general physician one day before her presentation. Upon further discussion, it was known that following an altercation with her family member, she had attempted suicide by consuming 200 mg of baclofen and then developed rapidly progressive symptoms of aphasia, mutism, and decreased oral intake. Laboratory tests, cerebrospinal fluid analysis, and neuroimaging were unremarkable. Electroencephalogram was normal. Bush-Francis Catatonia Rating Scale score was 27. She showed significant improvement following low-dose lorazepam administration. There are four reports in the literature of catatonia secondary to baclofen. The present report is the first to describe the occurrence of catatonia in a previously healthy individual. Analysis of these cases suggests a relationship between a history of psychotic symptoms and catatonia. All the reports were classified as probable by the Naranjo algorithm.


Catatonia , Psychotic Disorders , Humans , Adult , Female , Young Adult , Catatonia/chemically induced , Catatonia/diagnosis , Catatonia/drug therapy , Baclofen/adverse effects , Lorazepam , Psychotic Disorders/drug therapy
7.
Infect Chemother ; 53(2): 247-260, 2021 Jun.
Article En | MEDLINE | ID: mdl-34216119

BACKGROUND: The high rate of transmission and infection of coronavirus disease 2019 (COVID-19) is a public health emergency of major epidemiological concern. No definitive treatments have been established, and vaccinations have only recently begun. We aim to review the efficacy and safety of Interferon Beta (IFN-ß) in patients who have a confirmed COVID-19 diagnosis. MATERIALS AND METHODS: A search from PubMed, Science Direct, Cochrane, and Clinicaltrials.gov databases were conducted from December 2019 to December 2020 to review the efficacy and safety of IFN-ß in adult patients with COVID-19 confirmed. We included randomized controlled trials, case reports, and experimental studies. Correspondences, letters, editorials, reviews, commentaries, case control, cross-sectional, and cohort studies that did not include any new clinical data were excluded. RESULTS: Of the 66 searched studies, 8 were included in our review. These studies demonstrated that although IFN-ß did not reduce the time to clinical response, there was an increase in discharge rate at day 14 and a decrease in mortality at day 28. The time to negative reverse transcription polymerase chain reaction (RT-PCR) was shown to be significantly shortened in patients receiving IFN-ß, along with a lower nasopharyngeal viral load. Further, patients receiving IFN-ß had a less significant rise in IL-6. IFN-ß was shown to decrease intensive care unit (ICU) admission rate, the requirement of invasive ventilation in severe cases, and improve the survival rate compared to control groups. There were no severe adverse events reported. Our review found that patients who received early treatment with IFN-ß experienced significantly reduced length of hospitalization, mortality, ICU admission, and mechanical ventilation. A greater chance of clinical improvement and improved imaging studies was noted in patients who received IFN-ß. There were no reported deaths associated with the addition of IFN-ß. Further randomized trials involving more significant sample sizes are needed to better understand the effect of IFN-ß on survival in COVID-19. CONCLUSION: This review identified encouraging data and outcomes of incorporating IFN-ß to treat COVID-19 patients. IFN-ß has been shown to decrease hospital stay's overall length and decrease the severity of respiratory symptoms when added to the standard of care. Also, in some studies, it has been demonstrated to reduce the length of ICU stay, enhance survival rate, and decrease the need for invasive mechanical ventilation. There were minor side effects reported (neuropsychiatric symptoms and hypersensitivity reaction). However, randomized clinical trials with a large sample size are needed to assess IFN-ß's benefit precisely.

...